
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Coronary heart disease secondary prevention smoking cessation
Introduction
2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) [1]
2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) [1]
Smoking Cessation (DO NOT EDIT) [1]
| “ | Goal: Complete cessation. No exposure to environmental tobacco smoke. | ” |
| Class I |
| “1. Patients should be asked about tobacco use status at every office visit. [2][3][4][5][6] (Level of Evidence: B) ” |
| “2. Every tobacco user should be advised at every visit to quit. [4][5][6][7] (Level of Evidence: A) ” |
| “3. The tobacco user’s willingness to quit should be assessed at every visit. (Level of Evidence: C) ” |
| “4. Patients should be assisted by counseling and by development of a plan for quitting that may include pharmacotherapy and/or referral to a smoking cessation program. [4][5][8][6][9][7] (Level of Evidence: A) ” |
| “5. Arrangement for follow up is recommended. (Level of Evidence: C) ” |
| “6. All patients should be advised at every office visit to avoid exposure to environmental tobacco smoke at work, home, and public places. [10][11] (Level of Evidence: B) ” |
References
References
- ↑ 1.0 1.1 Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA; et al. (2011). “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation”. Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934.
- ↑ Rothemich SF, Woolf SH, Johnson RE; et al. (2008). “Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study”. Ann Fam Med. 6 (1): 60–8. doi:10.1370/afm.750. PMC 2203392. PMID 18195316.
- ↑ Rosser W, McDowell I, Newell C (1992). “Documenting smoking Status: Trial of three strategies”. Can Fam Physician. 38: 1623–8. PMC 2146014. PMID 21221363. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 4.2 “Systems Change: Treating Tobacco Use and Dependence”.
- ↑ 5.0 5.1 5.2 Cummings SR, Coates TJ, Richard RJ; et al. (1989). “Training physicians in counseling about smoking cessation. A randomized trial of the “Quit for Life” program”. Ann. Intern. Med. 110 (8): 640–7. PMID 2930094. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 6.2 “www.surgeongeneral.gov”.
- ↑ 7.0 7.1 Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005). “The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial”. Ann. Intern. Med. 142 (4): 233–9. PMID 15710956. Unknown parameter
|month=ignored (help) - ↑ Cummings SR, Richard RJ, Duncan CL; et al. (1989). “Training physicians about smoking cessation: a controlled trial in private practice”. J Gen Intern Med. 4 (6): 482–9. PMID 2685206.
- ↑ Duncan C, Stein MJ, Cummings SR (1991). “Staff involvement and special follow-up time increase physicians’ counseling about smoking cessation: a controlled trial”. Am J Public Health. 81 (7): 899–901. PMC 1405179. PMID 2053669. Unknown parameter
|month=ignored (help) - ↑ The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General. 2006. ISBN 0-16-076152-2.
- ↑ Institute of Medicine; Committee on Secondhand Smoke Exposure and Acute Coronary Events (2010). Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, D.C: National Academies Press. ISBN 0-309-13839-6.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
